BioNTech SE (NASDAQ:BNTX) is one of the best stocks to buy and hold for the next 6 months. On February 2, research firm ...
High-rolling investors have positioned themselves bullish on BioNTech (NASDAQ:BNTX), and it's important for retail traders to take note. \This activity came to our attention today through Benzinga's ...
MAINZ, Germany, December 3, 2025 – BioNTech SE (Nasdaq: BNTX, “BioNTech”) announced today that 184,071,410 shares of CureVac N.V. (Nasdaq: CVAC, “CureVac”), representing approximately 81.74% of ...
BioNTech exploits a wide array of computational discovery and therapeutic modalities with the intent of rapid development of novel biopharmaceuticals. Its diversified portfolio of oncology product ...
(RTTNews) - BioNTech SE (BNTX) on Wednesday announced that 184 million shares of CureVac, which is about 81.74 percent of the total shares, were successfully submitted by the December 3 deadline. This ...
Mainz, Germany, January 12, 2026 – BioNTech SE (Nasdaq: BNTX, “BioNTech” or “the Company”) will provide a strategic business update and outline the Company’s focus areas for 2026, including an ...
MAINZ, Germany, and ROCKVILLE, USA, December 6, 2025 (GLOBE NEWSWIRE) -- BioNTech SE (Nasdaq: BNTX, “BioNTech”) and OncoC4, Inc. (“OncoC4”) today presented data from the non-pivotal dose-confirmation ...
BioNTech SE Sponsored ADR (BNTX) shares rallied 11.8% in the last trading session to close at $118. This move can be attributable to notable volume with a higher number of shares being traded than in ...
Fintel reports that on November 10, 2025, HC Wainwright & Co. maintained coverage of BioNTech SE - Depositary Receipt (NasdaqGS:BNTX) with a Buy recommendation. As of November 9, 2025, the average one ...
Following recent challenges, these drugmakers could see solid clinical progress in the next 12 to 18 months. Both could launch products with significant sales potential and ride that wave through the ...
(RTTNews) - BioNTech SE (BNTX) and Bristol-Myers Squibb Company (BMY), Tuesday announced the first interim data from a global randomized Phase 2 trial, evaluating pumitamig in patients with locally ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results